Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.

The biochemical basis underlying the genetic polymorphism of drug N-acetylation was investigated using a combination of in vivo and in vitro assays for arylamine N-acetyltransferase (NAT) activity and content in human liver. The acetylator phenotype of 26 surgical patients was determined using caffe...

Celý popis

Podrobná bibliografie

Vydáno v:	J Clin Invest
Hlavní autoři:	Grant, D M, Mörike, K, Eichelbaum, M, Meyer, U A
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	American Society for Clinical Investigation 1990
Témata:	Research Article
On-line přístup:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC296518/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/2312737/ https://ncbi.nlm.nih.govhttps://doi.org/10.1172/JCI114527
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!